Made possible by a charitable contribution from
Navigation Tip: Click on blue text that’s italicized, underlined and in bold for link to more information.
We’re pleased to provide you with some of the latest
Prostate Cancer News You Can Use
. In addition to the following updates and information that may be of interest to you, the titles of prostate cancer news articles are listed below along with a link to the Us TOO web page that provides access to the full text for each article.
On October 12, we were in Detroit, MI, to present the
Prostate Cancer Pathways event and webcast. It was a featured event at the Karmanos Cancer Institute Cancer Symposium 2019! Medical experts covered treatment options including the latest therapies, genetics & genomic testing, sexual health & intimacy, erectile dysfunction, and anxiety & depression.
Video from the event will be posted within the next few weeks.
Keep a lookout for an email from us with the link.
We’d like to thank all Pathways event attendees and the online webcast audience; Karmanos Cancer Institute Wayne State University for hosting the event; patient moderators Joel Nowak and Jim Schraidt; expert presenters Dr. Zachery Reichert, Dr. Shelley L. Imholte, Dr. Bahaa S. Malaeb, and Dr. Gary McClain; and event sponsors Astellas/Pfizer Oncology, Janssen Oncology, Amgen, Clovis Oncology, Dendreon, Genomic Health, Timm Medical Technologies Inc., and Advanced Accelerator Applications.
Register now the Us TOO Pathways event in Chicago on Saturday, Nov. 9! Plan to attend in-person or watch the webcast with live audio and video. Don’t miss presentations and panel discussions on the following topics from some of the top medical experts in the country including:
• Radiation Oncology - Sean Sachdev, MD
• Medical Oncology - Maha Hussain, MD
• Men's Sexual Health - Nelson Bennett, Jr., MD
• Genetics - Brittany Szymaniak, PhD, CGC
• Urologic Oncology - Shilajit D. Kundu, MD
• Hematology and Oncology - Alicia Morgans, MD, MPH
• Hematology and Oncology - David J. VanderWeele, MD, PhD
for more information on the Chicago Pathways event and
Congress expanded the geographic limits for exposure to Agent Orange
. Veterans who served on vessels within 12 nautical miles seaward from the demarcation line of waters of Vietnam and Cambodia as defined in Public Law 116-23 (Blue Water Navy) between January 9, 1962, and May 7, 1975, are presumed to have been exposed to herbicides such as Agent Orange and may be entitled to service connection for conditions related to that exposure. Read more in the
and find additional information including a list of conditions in the
The call for nominations is now open for the
second annual Cancer Community (C2) Awards!
The C2 awards spotlight those who are at the forefront of cancer care and celebrate the unsung heroes who make an enormous difference to patients and their families. Learn more at
The National Alliance of State Prostate Cancer Coalitions – “The Prostate Cancer Alliance”- is pleased to present its 15th Annual Meeting GALA on Saturday, October 19, 2019 at 6:30 pm.
for more information.
Registration is now open for Prostate Cancer International's
4th FREE conference for patients and caregivers
Saturday, November 2nd in Virginia Beach, VA.
for more information.
NEWS YOU CAN USE ARTICLES:
Please note that the content below lists only the title of the article rather than a direct link to the content. For access to the full article
- Johns Hopkins University Details Findings in Robotics (Robotic Transrectal Ultrasound Guided Prostate Biopsy)
- Survey reveals low levels of awareness in men about prostate health and function
- Researchers from University of Colorado Discuss Findings in Prostate Cancer (Illness Uncertainty, Partner Support, and Quality of Life: a Dyadic Longitudinal Investigation of Couples Facing Prostate Cancer)
- Oklahoma center tests drug for prostate cancer patients on active surveillance
- Increased risk of prostate cancer in men with BRCA2 gene fault
- Investigators at University of Wisconsin Detail Findings in Prostate Cancer (Incidence of Androgen Receptor and Androgen Receptor Variant 7 Coexpression In Prostate Cancer)
- Search tightens for genes driving prostate cancer
- FDA Approves Prostate Cancer Drug ERLEADA for New Indication
- Data on Prostate Cancer Reported by Researchers at University of Heidelberg School of Medicine (The BRCA2 mutation status shapes the immune phenotype of prostate cancer)
- Long-term hormone tx increases mortality risk for men with low PSA after prostate surgery
- Promising prostate cancer drug candidates identified by Bath scientists
- Investigators from Federat University Release New Data on Prostatectomy (Self-reliance and stoicism as predictors of distress following radical prostatectomy in the context of place of residence)
- Study: Biomarker in urine may offer noninvasive detection of prostate cancer
- Investigators from Stanford University Zero in on Cancer (Prostate Magnetic Resonance Imaging Interpretation Varies Substantially Across Radiologists)
- Studies in the Area of Prostate Cancer Reported from University of Alabama at Birmingham. (Self-Identified African Americans and prostate cancer risk: West African genetic ancestry is associated with prostate cancer diagnosis and with higher ...)
- New Prostate Cancer Findings from Sisli Etfal Education and Research Hospital Described (Bridging the Imaging Gap: PSMA PET/CT Has a High Impact on Treatment Planning in Prostate Cancer Patients with Biochemical Recurrence-A Narrative Review of ...)
- Reports from Peter MacCallum Cancer Center Advance Knowledge in Prostate Cancer (Guiding management of therapy in prostate cancer: time to switch from conventional imaging to PSMA PET?)
- Link between assisted reproduction and risk for prostate cancer
- Semen miRNAs could be non-invasive biomarkers for prostate cancer
- Researchers at Princess Grace Hospital Target Prostate Cancer (Chemoprevention of Prostate Cancer by Natural Agents: Evidence from Molecular and Epidemiological Studies)
- Data on Prostate Cancer Discussed by Researchers at University of York (Resolution of Cellular Heterogeneity in Human Prostate Cancers: Implications for Diagnosis and Treatment)
- MSNBC host Chris Matthews had prostate cancer surgery. What comes next?
AstraZeneca announced detailed results from the
Phase III PROfound trial
, showing delayed cancer progression in men with metastatic castration-resistant prostate cancer (mCRPC) who have a mutation in their homologous recombination repair (HRRm) genes and whose disease had progressed on prior treatment with new hormonal agent treatments.
to read the US press release on the data that was presented during the 2019 European Society of Medical Oncology (ESMO) congress in Barcelona, Spain.
Watch for the November issue of the Us TOO Hot SHEET newsletter, and let us know how we can help provide you with educational resources, support services and personal connections to others in the prostate cancer community.
All the best,